Investor Relations

We are a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders. We improve compliance, absorption, and more with our proprietary drug delivery technology.

Company Profile

Press Releases
Sep 27, 2022

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on leveraging its proprietary Lip'ral platform to develop differentiated products through the oral delivery of previously...

Sep 26, 2022

Company to apply its proprietary Lip'ral oral drug delivery technology to advance a pipeline of differentiated products for Central Nervous System (CNS) disorders Initial focus on oral delivery of...

Sep 22, 2022

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on leveraging its proprietary Lip'ral platform to augment therapeutics through effective oral delivery by developing...

Sep 15, 2022

FDA agrees with Lipocine establishing LPCN 1154 pathway to efficacy through a pharmacokinetic (PK) bridge to an approved IV infusion brexanolone Lipocine has demonstrated that the brexanolone...

ABOUT LIPOCINE INC.

Lipocine Inc. is a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders using its proprietary drug delivery technologies. Lipocine's clinical development pipeline includes TLANDO, LPCN 1144, TLANDO XR (“LPCN 1111”), LPCN 1148 and LPCN 1107. TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate, is designed to help restore normal testosterone levels in hypogonadal men. LPCN 1144, an oral prodrug of bioidentical testosterone, recently completed a proof-of-concept clinical study demonstrating the potential utility in the treatment of pre-cirrhotic NASH. TLANDO XR, a novel oral prodrug of testosterone, originated and is being developed by Lipocine as a next-generation oral testosterone product with potential for once-daily dosing. In a phase 2 clinical evaluation when administered as once daily or twice daily TLANDO XR met the typical primary and secondary end points. LPCN 1148 is an oral prodrug of bioidentical testosterone targeted for the treatment of NASH cirrhosis. LPCN 1107 is potentially the first oral hydroxyprogesterone caproate product candidate, with end of phase 2 meeting completed, indicated for the prevention of recurrent preterm birth and has been granted orphan drug designation by the FDA. For more information, please visit www.lipocine.com

Management Directors

STOCK INFO
NASDAQLPCN
SEC FILINGS
NASDAQLPCN
Events
Tuesday, October 12, 2021
3:30pm - 4:30pm EDT
Monday, September 27, 2021 - Thursday, September 30, 2021
1:20pm EDT
Monday, September 13, 2021
7:00am - 8:00am EDT

ALL EVENTS >

Contact Us

Krista Fogarty phone: (801) 994-7383 email: kf@lipocine.com